SEC Filings

Investors & Media

Transformative science, targeted medicines

Blueprint Medicines is a fully integrated global biopharmaceutical company that invents life-changing medicines across two strategic focus areas of allergy/inflammation and oncology/hematology. Our approach combines deep scientific expertise, modality-agnostic drug discovery capabilities, and a proven track record of R&D success. Currently, we are commercializing our approved medicine AYVAKIT/AYVAKYT^® (avapritinib) in the U.S. and Europe, as well as in other regions of the world through partnerships.

SEC Filings

Filing date	Form	Description	View
Dec 01, 2020	8-K	Report of unscheduled material events or corporate event	View HTML 0001558370-20-014130.pdf 0001558370-20-014130.rtf 0001558370-20-014130.xls EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
Nov 18, 2020	4	Statement of changes in beneficial ownership of securities	View HTML 0001179110-20-011196.pdf 0001179110-20-011196.rtf 0001179110-20-011196.xls
Nov 18, 2020	4	Statement of changes in beneficial ownership of securities	View HTML 0001179110-20-011198.pdf 0001179110-20-011198.rtf 0001179110-20-011198.xls
Nov 18, 2020	4	Statement of changes in beneficial ownership of securities	View HTML 0001179110-20-011197.pdf 0001179110-20-011197.rtf 0001179110-20-011197.xls
Nov 05, 2020	4	Statement of changes in beneficial ownership of securities	View HTML 0001179110-20-010844.pdf 0001179110-20-010844.rtf 0001179110-20-010844.xls
Nov 04, 2020	4	Statement of changes in beneficial ownership of securities	View HTML 0001179110-20-010821.pdf 0001179110-20-010821.rtf 0001179110-20-010821.xls
Oct 29, 2020	8-K	Report of unscheduled material events or corporate event	View HTML 0001558370-20-011983.pdf 0001558370-20-011983.rtf 0001558370-20-011983.xls EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
Oct 29, 2020	10-Q	Quarterly report which provides a continuing view of a company's financial position	View HTML 0001558370-20-012041.pdf 0001558370-20-012041.rtf 0001558370-20-012041.xls EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
Oct 27, 2020	4	Statement of changes in beneficial ownership of securities	View HTML 0001179110-20-010677.pdf 0001179110-20-010677.rtf 0001179110-20-010677.xls
Oct 21, 2020	4	Statement of changes in beneficial ownership of securities	View HTML 0001179110-20-010626.pdf 0001179110-20-010626.rtf 0001179110-20-010626.xls

Investors & Media

Transformative science, targeted medicines

SEC Filings

Pagination